ZHENGYE BIOTECHNOLOGY-A

ZYBT · NASDAQ

Updated at 2026-10-17 21:28:14

$1.40-6.66%
Today's High
$1.57
Today’s Low
$1.38
ZHENGYE BIOTECHNOLOGY-A (ZYBT) Stock Price & Market Data
Search empty state illustration
...

Candlestick trends are for reference. Refer to the trading page for actual data.

Key Statistics

Previous Open
$1.50
Previous Close
$1.40
Volume
81.28K
Market Cap
$40.43M
P/E Ratio
--
EPS
$-1.93

Previous Day Range

$1.38$1.57

52-Week Range

$0.61$8.01

Company Overview

Sector
HEALTHCARE
Industry
Pharmaceuticals
Sub-industry
DRUG MANUFACTURERS - SPECIALTY & GENERIC
Headquarters
NO.1 LIANMENG ROAD, JILIN, CHINA
Country
CN
Listing Date
2025-01-07
Fiscal Year End
December
Shares Outstanding
29.73M
CIK
0001975641

Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm specializing in the development and commercialization of advanced biopharmaceutical products aimed at addressing critical medical needs. With a robust pipeline and proprietary technologies, ZYBT is well-positioned to enhance treatment outcomes across multiple therapeutic areas. The company's commitment to rigorous research and development, coupled with a focus on quality and innovation, underscores its potential for sustainable growth and value creation for investors in the competitive biotechnology landscape.

Financial Metrics

Revenue

2026-03-31

$53.03M

2025-09-30

$27.01M

Operating Expenses

2026-03-31

$45.26M

2025-09-30

$23.05M

Net Income

2026-03-31

-$47.22M

2025-09-30

-$24.05M

Net Profit Margin

2026-03-31

-89.04%

2025-09-30

-89.04%

Earnings Per Share

2026-03-31

--

2025-09-30

$-0.46

Earnings Before Interest, Taxes, Depreciation, and Amortization

2026-03-31

-$27.4M

2025-09-30

-$13.96M

Effective Tax Rate

2026-03-31

-40.1%

2025-09-30

-40.1%

FAQs

Risk Warning

Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.